Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

Ezra E.W. Cohen, J.-P. Machiels, Xiuyu Julie Cong et al.|Annals of Oncology|2017

Cited by 80